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Abstract
Colorectal cancer is driven by the accumulation of driver
mutations, but the contributions of speciﬁcmutations to different
steps in malignant progression are not fully understood. In this
study, we generated mouse models harboring different combina-
tions of key colorectal cancer driver mutations (Apc, Kras, Tgfbr2,
Trp53, Fbxw7) in intestinal epithelial cells to comprehensively
investigate their roles in the development of primary tumors and
metastases. ApcD716 mutation caused intestinal adenomas and
combination with Trp53R270H mutation or Tgfbr2 deletion
induced submucosal invasion. The addition ofKrasG12Dmutation
yielded epithelial–mesenchymal transition (EMT)-like morphol-
ogy and lymph vessel intravasation of the invasive tumors. In
contrast, combinations of ApcD716with KrasG12D and Fbxw7muta-
tion were insufﬁcient for submucosal invasion, but still induced
EMT-like histology. Studies using tumor-derived organoids
showed that KrasG12D was critical for liver metastasis following
splenic transplantation, when this mutation was combined with
either ApcD716 plus Trp53R270H or Tgfbr2 deletion, with the highest
incidence of metastasis displayed by tumors with a ApcD716
KrasG12D Tgfbr2/ genotype. RNA sequencing analysis of tumor
organoids deﬁned distinct gene expression proﬁles characteristic
for the respective combinations of driver mutations, with upre-
gulated genes in ApcD716 KrasG12D Tgfbr2/ tumors found to be
similarly upregulated in specimens of human metastatic colorec-
tal cancer. Our results show how activation of Wnt and Kras with
suppression of TGFb signaling in intestinal epithelial cells is
sufﬁcient for colorectal cancer metastasis, with possible implica-
tions for the development of metastasis prevention strategies.
Signiﬁcance:Theseﬁndings illuminate howkey drivermutations
in colon cancer cooperate to drive the development of metastatic
disease, with potential implications for the development of suitable
prevention strategies. Cancer Res; 78(5); 1334–46. 2017 AACR.
Introduction
Colorectal cancer is a leading cause of cancer-related death
worldwide (1, 2), and the 5-year survival rate drops signiﬁcantly
to about 14% for patients with metastasis (3). It is therefore
extremely important to clarify the biological mechanisms of
malignant progression to identify novel therapeutic target path-
ways. The gradual accumulation of genetic alterations in driver
genes is known to cause development andmalignant progression
of colorectal cancer and is an established concept of multistep
tumorigenesis (4, 5). Recent genome-wide analyses have con-
ﬁrmed the presence of frequently mutated driver genes in human
colorectal cancer (6, 7). Using organoid culture systems, it has
been shown that the introduction of genetic alterations in driver
genes, APC, KRAS, SMAD4, TP53, and PIK3A, in intestinal epi-
thelial cells induces tumorigenesis (8–10).
These driver mutations are classiﬁed as cancer signaling path-
ways (11), and the possible mechanisms of each mutation in
tumorigenesis have been well studied. For example, loss of APC
results in Wnt signaling activation, leading to the acquisition of
stemness (12). KRAS plays a major role in tumorigenesis through
the activation of RAF–MAPK and PI3K pathways (13). In contrast,
TGFb signaling promotes differentiation of epithelial cells, thus
playing a tumor suppressor role in colorectal cancer (14). Fur-
thermore, FBXW7 is a component of the ubiquitin ligase complex
that degrades proto-oncogene products, thereby functioning as a
tumor suppressor (15), and the disruption of Fbxw7 promotes
intestinal tumorigenesis (16, 17). Recent results indicate that
mutant p53 alters the gene expression globally by gain-of-func-
tion mechanism, which promotes tumorigenesis (18, 19).
Moreover, the effects of simultaneous mutations in combina-
tion on colorectal cancer have also been genetically studied. It has
1Division of Genetics, Cancer Research Institute, Kanazawa University, Kana-
zawa, Japan. 2AMED-CREST, AMED, Japan Agency for Medical Research and
Development, Tokyo, Japan. 3Department of Surgery, Kyushu University Beppu
Hospital, Beppu, Japan. 4Division of Health Medical Computational Science,
Health Intelligence Center, Institute of Medical Science, The University of Tokyo,
Tokyo, Japan. 5Division of Pathology, Exploratory Oncology Research and
Clinical Trial Center, National Cancer Center, Kashiwa, Japan. 6Exploratory
Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa,
Japan. 7Department of Molecular and Cellular Biology, Medical Institute of
Bioregulation, Kyushu University, Fukuoka, Japan. 8Department of Computa-
tional Biology and Medical Sciences, Graduate School of Frontier Sciences,
University of Tokyo, Chiba, Japan. 9Theragen Etex Bio Institute, Suwon, Korea.
10Precision Medicine Research Center, Advanced Institutes of Convergence
Technology and Department of Transdisciplinary Studies, Graduate School of
Convergence Science and Technology, Seoul National University, Suwon, Korea.
11Nano Life Science Institute (Nano LSI), KanazawaUniversity, Kanazawa, Japan.
Note: Supplementary data for this article are available at Cancer Research
Online (http://cancerres.aacrjournals.org/).
E. Sakai and M. Nakayama contributed equally to this article.
Corresponding Author: Masanobu Oshima, Division of Genetics, Cancer
Research Institute, Kanazawa University, Kanazawa 920-1192, Japan. Phone:
81-76-264-6760; Fax: 81-76-234-4519; E-mail: oshimam@staff.kanazawa-u.ac.jp
doi: 10.1158/0008-5472.CAN-17-3303
2017 American Association for Cancer Research.
Cancer
Research
Cancer Res; 78(5) March 1, 20181334
on March 27, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst December 27, 2017; DOI: 10.1158/0008-5472.CAN-17-3303 
been shown that the suppression of TGFb pathway or expression
of mutant p53 in ApcD716 mice induces the submucosal invasion
of intestinal tumors (20–22). Moreover, the Kras mutation in
addition to Apc and Trp53 mutation causes invasion and metas-
tasis (23, 24). However, despite these ﬁndings from genetic
studies, the big picture regarding how speciﬁc combinations of
driver mutations promote each step of malignant progression in
the primary tumors and metastatic foci remains unclear.
In this study, we generated mouse models carrying the ApcD716
mutation together with conditional mutant alleles of KrasG12D,
Trp53R270H, Tgfbr2/, or Fbxw7/ in various combinations and
examined their intestinal tumor phenotypes. Using these mouse
models and allografts of tumor-derived organoids, we found the
speciﬁc combinations of the driver mutations that were respon-
sible for submucosal invasion, epithelial–mesenchymal transi-
tion (EMT)-like morphology, intravasation, and metastasis. Par-
ticularly, the combinations including ApcD716 KrasG12D Tgfbr2/
mutations caused efﬁcient liver metastasis. Moreover, RNA
sequencing (RNA-Seq) analysis corroborated the distinct expres-
sion proﬁles for the speciﬁc mutational combinations that are
associated with distinct malignant phenotypes in both mice and
human. Accordingly, targeting the pathways that regulate speciﬁc




ApcD716, Fbxw7ﬂox/ﬂox, and villin-CreER mice were described
previously (25–27). Tgfbr2ﬂox/ﬂox, Trp53LSLR270H, and KrasLSL*G12D
mice were obtained from the Mouse Repository (NCI-Frederick,
Frederick, MD; refs. 28–30). Primer sequences for genotyping
are previously reported except for Trp53 forward primer, 50-CCTG-
CCAGCTCCGAAAGATT-30. The genetic background of all strains
used in this study is C57BL/6. All mice were treated with tamox-
ifen intraperitoneally at 4mg/mouse once a week from8weeks of
age for 4weeks. For the survival curve analysis,micewereobserved
until 270 days of age, and the mice were euthanized when they
showed a moribund phenotype. The total numbers of polyps in
both the small intestine and colon were scored at 13–16 weeks of
age (n ¼ 3–5 for each genotype). NOD/Shi-scid Il2rg/ mice
(NSGmice) andC57BL/6micewerepurchased (CIEA). All animal
experiments were performed with the protocol approved by the
Committee on Animal Experimentation of Kanazawa University.
Histology and IHC
The primary intestinal tumors and liver metastasized tumors
were ﬁxed in 4% paraformaldehyde, parafﬁn-embedded, and
sectioned at 4-mm thickness. The sections were stained with
hematoxylin and eosin (H&E) or Masson's trichrome stain. Anti-
bodies against E-cadherin (R&D Systems), aSMA (Sigma), F4/80
(Serotec), CD3e (Santa Cruz Biotechnology), Ki67 (Life Technol-
ogy), Lyve-1 (Acris Antibodies GmbH), vWF (DakoCytomation,
Denmark), Snail2 (Bioss), CD4, CD8, and CD45R (BD Pharmin-
gen) were used as the primary antibody. Staining signals were
visualized using the Vectastain Elite Kit (Vector Laboratories). For
ﬂuorescent IHC, Alexa Fluor 594- or Alexa Fluor 488–conjugated
antibodies (Molecular Probes) were used as the secondary
antibody. The histologic classiﬁcation of the tumors was per-
formed according to the Japanese Classiﬁcation of Colorectal
Carcinoma (31).
The mean Ki67-labeling indices were calculated as the number
of Ki67-positive cells per total number of tumor cells by counting
5 independent microscopic ﬁelds (200) for three independent
tumors per mouse (n ¼ 3) or 3–8 independent foci of liver
metastasized tumors (NSG mice n ¼ 3 for each, C57BL/6 mice
n ¼ 1–5).
The immunostaining-positive areas for F4/80,aSMAandCD3e
in the microscopic ﬁelds were measured using the Hybrid cell
count software program of All-In-Onemicroscope (Keyence). For
the primary tumors, the ratio of the aSMA immunostaining-
positive area was calculated from 3–5 polyps per mouse
(n ¼ 3). For the liver metastasized tumors, the ratios of
aSMA, F4/80, and CD3e immunostaining-positive areas were
calculated from 3 to 12 foci per mouse (NSG mice n ¼ 3,
C57BL/6 mice n ¼ 1–5).
Scoring invasion efﬁciency and solitary cells
The total numbers of invading polyps in submucosa and total
polyps were counted on the H&E-staining sections of whole
intestine and the invasion efﬁciency was calculated (n ¼ 4–5).
Solitary tumor cells were detected by IHC for E-cadherin, and the
numbers of solitary cells were counted on the sections (n¼ 4–18)
while the mean numbers were calculated per 1-mm2 area using
the Hybrid cell count software program (Keyence).
Organoid culture and transplantation experiments
The organoid cultures were prepared from small intestinal
tumors, as described previously (22). Authentication of the orga-
noid cells was done by genotyping for the respective combined
mutations. Cryopreserved stocks were established after testing,
and experiments were performed within 5–10 passages following
thaw of frozen stocks. Mycoplasma testing was done by indirect
immunoﬂuorescence test andnested PCR. The cultured organoids
were mechanically dissociated, and 3  105 organoid cells were
injected with Matrigel into the spleen of NSG mice (n ¼ 3–5) or
C57BL/6mice (n¼ 4–18). At four weeks after transplantation, the
liver and lung were examined histologically. The multiplicity of
metastatic foci in the liver was scored by the measurement of the
metastasized tumor areas on H&E sections and the calculated
percentages per total liver (NSG, n ¼ 3–5; C57BL/6, n ¼ 5–12).
Next-generation RNA sequencing
Total RNA was extracted from organoid cells using an RNeasy
plus Micro kit (Qiagen). RNA-Seq Libraries were prepared using a
SureSelect Strand Speciﬁc RNAReagent Kit (Agilent Technologies)
according to the manufacturer's protocol. Thirty-six bp of single-
end sequencing was performed using an Illumina HiSeq3000
(Illumina). Obtained reads were aligned to UCSC mm10 using
tophat2. For the expression estimation,we counted the number of
reads, which uniquely mapped to the exon of RefSeq transcripts,
and calculated the reads per kilo-base of exon model per million
mapped reads (RPKM) as the expression value. The sequencing
data were deposited in the DNA Data Bank of Japan (DDBJ,
accession #DRA005647). Clean reads that average quality scores
for all libraries were more than Q30 were aligned to the mouse
reference (Ensembl 85) using TopHat2 (32).
Hierarchical clustering and GO term analysis
Gene expression quantiﬁcation was performed using Cuf-
ﬂinks (33). Differential expression analysis between samples with
Malignant Progression of Colon Cancer by Driver Combination
www.aacrjournals.org Cancer Res; 78(5) March 1, 2018 1335
on March 27, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst December 27, 2017; DOI: 10.1158/0008-5472.CAN-17-3303 
replicates was performed using Cuffdiff with the cut-off set at
P < 0.01 and1.5-fold change.Hierarchical clustering for selected
geneswere analyzedwithMeV (http://mev.tm4.org) using Euclid-
ean distance and complete linkage method. Functional annota-
tion for module members were performed by DAVID (34),
and relevant gene ontology (GO) terms were selected with a
cutoff of P < 0.01.
Processing genomic data from The Cancer Genome Atlas
project
We used publicly available, level 3 data of The Cancer Genome
Atlas (TCGA) in the current study. Clinical information and
mRNAexpressiondata obtainedbyRNA-seqof the TCGAsamples
were downloaded from the USCS Cancer Browser (https://
genome-cancer.ucsc.edu). The patients' clinical data and molec-
ular subtype status of the tumors were referred from the TCGA
database (6). Among colorectal cancer samples, 343 tumor sam-
ples that included RNAseq data and metastasis information (M0,
n ¼ 285; M1, n ¼ 58) were analyzed for the current study.
The principal component analysis
The RPKM values from RNA-seq of intestinal tumor organoids
were subjected to quantile normalization and 5,000 genes with
the highest variances were input to principal component analysis
(PCA). PCA was performed using the prcomp function imple-
mented in the R software (https://www.r-project.org).
Statistical analysis
The data were analyzed using an unpaired t test and are
presented as the means SD. A value of P < 0.05 was considered
as statistically signiﬁcant. The signiﬁcance of the differences of
RNA expressions according to same or more than two groups was
calculated by the Wilcoxon rank-sum test. For RNA-seq data,
statistical analyses and data presentations were performed in R
language 3.1.3 (http://www.r-project.org)
Results
Generation of mouse models carrying driver mutations in
combination
We crossed ApcD716 (A), Krasþ/LSL-G12D (K), Tgfbr2ﬂox/ﬂox (T),
Trp53þ/LSL-R270H (P), Fbxw7ﬂox/ﬂox (F), and villin-CreER mice to
generate compound mutant mice carrying driver mutations in
different combinations (Fig. 1A and B). These are frequently
mutated genes in human colorectal cancer (6, 7). Of note,
missense-type mutations of p53 are found in about 50% of
human colorectal cancer (6), andwe recently showed thatmutant
p53R270H induces the submucosal invasion of intestinal tumors
(22). Accordingly, we used Trp53R270H mice in this study to
examine the gain-of-function mechanism of mutant p53. In all
mice, intestinal tumors were initiated by somatic loss of wild-type
Apc, that causes Wnt signaling activation (25). The treatment of
compound mice with tamoxifen induced genetic alterations in
conditional alleles in an intestinal epithelia-speciﬁc manner, and
we conﬁrmed the tamoxifen-induced recombination in the intes-
tinal tumor cells (Supplementary Fig. S1).
Although none of compound mice developed spontaneous
metastasis (see below), the mean life spans were decreased
depending on the increased numbers of driver mutations
(Fig. 1C), suggesting that the accumulation of driver mutations
affects systemic conditions through secreted factors.
Increased multiplicity of intestinal tumors by ApcD716 KrasG12D
combination
We examined the number and size of intestinal polyps in A, AK,
AKP, AKT, ATP, AKTP, and AKTPFmice. Intestinal tumors of other
genotype mice with the Fbxw7 mutation were not polypotic and
thus uncountable (see below). Notably, the polyp number
increased signiﬁcantly in mice that carried the AK combination,
that is, AK, AKP, AKT, AKTP, and AKTPF, in comparison to that in
A and ATP mice, indicating that Kras activation increases the
multiplicity of tumors (Fig. 1D and E). Interestingly, the ratio of
small polyps (<1mm) dramatically increased inmice carrying AK
combination (Fig. 1F), andmost small adenomas were located in
the upper part of the mucosa without connecting to the crypt
bottom (Supplementary Fig. S2). Therefore, these small adeno-
mas in KrasG12D mice may be eliminated by shedding to the
lumen, which may explain the increase in the ratio of small
polyps. We previously showed that ApcD716 mouse tumor cells
cannot survive without generation of COX-2–expressing micro-
environment (35, 36). Thus, it is possible that Kras activation
contribute to the survival of tumor cells through the generation of
such microenvironment.
Submucosal invasion by ApcD716 Trp53R270H and ApcD716
Tgfbr2/ combinations
Histologic types of all genotype mouse tumors are shown in
Supplementary Table S1. Notably, mice carrying AP or AT muta-
tions, that is, AKP, ATP, AKT, ATPF, AKTF, AKTP, and AKTPFmice,
developed adenocarcinomas with invasion to submucosa or
deeper, while invasive tumors were not found in A, AK, and
AKF mice (Fig. 2A and B). These results are consistent with the
previous ﬁndings that TGFb signaling suppression or mutant
p53R270H expression induces submucosal invasion intestinal
tumors (20–22).
Notably, the ratio of stromal volume was signiﬁcantly
increased in the invaded submucosal area with the increased
number of aSMA-expressing myoﬁbroblasts in comparison
with those in mucosal area regardless of mutation types (Fig.
2A and C). Increased collagen ﬁber deposition detected by
Masson's trichrome staining was consistently found in the
submucosal invasion area (Supplementary Fig. S3A). These
results indicate that desmoplastic reaction is induced in the
submucosa, but not in the mucosa. It has been shown that such
ﬁbrotic reactive stroma plays a role in malignant progression
through the secretion of various factors including TGFb and
Wnt ligands (37). Tumor cells may therefore acquire malignant
characteristics in the submucosa by exposure to desmoplastic
microenvironment.
Interestingly, the proliferation rates of tumor cells were signif-
icantly lower in the submucosal area than in mucosal area,
possibly due to the effect of desmoplastic stroma (Fig. 2D;
Supplementary Fig. S3B). We noted no signiﬁcant difference in
the proliferation rates in the mucosa of all genotypes compared
with that in simple ApcD716mouse adenomas, indicating that any
of the driver mutations does not accelerate the proliferation in
primary tumors.
EMT-like morphology in submucosa and mucosa by distinct
combinations
EMT is a hallmark of cancer malignancy (38). We found
tumor cell clusters that had lost their glandular architecture and
solitary tumor cells in the submucosa, which showed the nuclear
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Figure 1.
The generation of mouse models and intestinal polyp phenotypes. A, Schematic drawing of mutant alleles of each driver gene (top). Schedule for
tamoxifen (Tam) treatment (bottom). B, Combinations of driver gene mutations in the respective genotype mice. C, The survival curves of each compound
mutant strain are shown. D, Size classiﬁcation of noninvasive and invasive intestinal polyps of the indicated compound mutant mice (n ¼ 3). Each dot
shows an individual polyp. E, The number of the intestinal polyps in indicated compoundmutant mice (mean SD).  , P <0.05. F,Ratio of intestinal polyps j 1 mm
(orange) and j < 1 mm (blue) in diameter in the indicated genotype mice.
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accumulation of the EMT marker Snail2 (Fig. 3A; Supplementary
Fig. S3C). Of note, these invasive tumor cells still expressed
E-cadherin, so we classiﬁed them as "EMT-like." Importantly, the
number of solitary cells in the submucosa was markedly high in
AKP, AKT, AKTP, AKTF, and AKTPF mouse tumors that carried
AKP or AKT combination but rarely found in ATP and ATPF mice
(Fig. 3A and B, right). These results indicate that Kras activation
together with mutant p53R270H expression or TGFb suppression
can induce EMT-likemorphologywhen tumor cells are exposed to
a desmoplastic microenvironment in submucosa. In contrast,
solitary tumor cells were found in themucosal area of AKF, AKTF,
and AKTPF mice that carried AKF combination (Fig. 3A and B,
left), suggesting that the combination of Kras and Fbxw7 muta-
tions induces EMT-like morphology without the support of a
desmoplastic microenvironment, although AKF combination is
not sufﬁcient for invasion.
Figure 2.
Submucosal invasion of the primary
intestinal tumors in mice carrying AP
or AT mutations. A, Representative
histology sections of the intestinal
polyps of the indicated genotype mice
(top, H&E low magniﬁcation; middle,
highmagniﬁcation of the boxed area in
top; bottom, aSMA immunostaining).
The dotted lines in middle and
bottom indicate the location of the
muscularis mucosae. Arrowheads,
invading tumor cells in the submucosa.
Scale bars, 200mm.B, The efﬁciency of
submucosal invasion in the indicated
genotype mice (mean  SD). ND, not
detected.  , P < 0.05. C, Percentages
of aSMA immunostaining–positive
area in mucosal (top) and submucosal
(bottom) tumors in the indicated
genotype mice (mean  SD).
 , P < 0.05 versus mucosal area for
each genotype. D, Percentages of
Ki67-positive tumor cells in mucosal
(top) and submucosal (bottom)
tumors in the indicated genotype
mice (mean  SD).  , P < 0.05 versus
mucosal area for each genotype.
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Importantly, intravasation into the Lyve-1–expressing lymph
vessels was found in AKT, AKTP, and AKTPF mouse tumors but
rarely found in other genotype mice (Fig. 3C). Furthermore,
intravasation to the blood vessels was also found in the AKTPF
mice. The AKT combination may therefore induce intravasation
with higher efﬁciency than the AKP or AKF combination.
Distinct histologic type and accelerated tumorigenesis by
ApcD716 KrasG12D Fbxw7/ combinations
It has been shown that FBXW7 plays a role in the differen-
tiation of intestinal epithelia (16, 17), suggesting that Fbxw7
mutation may alter the tumor morphology. Interestingly, the
histologic type of AKF, AKTF, and AKTPF genotype mouse
Figure 3.
EMT-like morphology and intravasation of the primary tumors in mice carrying AKP or AKT mutations. A, Representative IHC sections for E-cadherin in
the submucosal invasion area of AKP, AKT, ATP, AKTP, AKTF, ATPF, and AKTPF mouse tumors and the mucosal area of AKF mouse tumor. The insets
indicate enlarged images of solitary or clustered tumor cells. Arrowheads, solitary or clustered tumor cells. Scale bars, 100 mm.B, Themean number of solitary tumor
cells per mm2 area in mucosal (left) and submucosal (right) tumors of the indicated genotype mice (mean  SD). Each dot indicates individual mice.  , P < 0.05. C,
Representative photographs of ﬂuorescence IHC for Lyve-1 or vWF (green), E-cadherin (red), and nuclear counterstainingwith DAPI (blue) in the submucosal region
of intestinal tumors of the indicated genotype mice. Arrowheads, E-cadherin–positive tumor cells in the Lyve-1–positive lymph vessels or vWF-positive capillary
vessel. The insets indicate the enlarged images of tumor cells with intravasation. Scale bars, 200 mm.
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tumors that included the AKF combination mutations was
villous-type, while other genotype mouse tumors were glan-
dular-type (Supplementary Fig. S4A). Because it was technically
difﬁcult to assess the tumor multiplicity of AKF common mice,
the tumor distribution was measured by the length ratio on
histology sections (Supplementary Fig. S4B). Notably, the
tumor distribution was signiﬁcantly increased in the AKF and
AKTF mice compared with other genotype mice that did not
carry the AKF combination (Supplementary Fig. S4B and S4C).
These results indicate that the combination of Kras activation
and Fbxw7 disruption accelerates tumor growth in addition to
inducing EMT-like morphology, and these properties are inde-
pendent of the invasion ability.
Efﬁcient liver metastasis by the ApcD716 KrasG12D Tgfbr2/
combination
We detected no spontaneous metastasis in any genotype mice
examined, indicating that the accumulation of these driver muta-
tions is not sufﬁcient for metastasis. We therefore established
organoids from the tumors of A, AK, AP, AT, ATP, ATPF, AKP, AKT,
AKTF, AKTP, and AKTPF mice and transplanted them to the
spleens of immunodeﬁcient NSG mice as well as immunocom-
petent C57BL/6 mice to examine their ability of metastasis to the
liver (Fig. 4A). At 4 weeks after spleen injection to NSG mice,
tumor organoids with 3 mutations except for ATP (i.e., AKP,
AKT, ATPF, AKTF, AKTP, and AKTPF) developed metastatic
tumors with 100% incidence. Among them, the multiplicity of
metastasis was signiﬁcantly higher in the AKT common orga-
noids, that is, AKT, AKTF, AKTP, and AKTPF, than in those of AKP
or ATPF (Fig. 4B). The organoids carrying AKT combination
efﬁciently formed metastatic tumors also in C57BL/6 mice, while
the incidences of metastasis of AKP and ATPF in C57BL/6 mice
were 10% and 0%, respectively (Fig. 4A, C, and D). These results
indicate that Wnt activation, Kras activation, and TGFb suppres-
sion by AKTmutations are the core combination for efﬁcient liver
metastasis. Notably, additional mutations in Trp53 and Fbxw7 to
AKT, that is, AKTP and AKTPF, induced the development of lung
metastasis after the spleen injection of organoids, which was not
found in other genotypes (Fig. 4A). Furthermore, AKTPF orga-
noids showed the highest mean multiplicity of liver metastasis
among the AKT common organoids.
Desmoplasia and T-cell inﬁltration in metastasized tumors
Histologically, metastasized tumors were diagnosed as mod-
erately to poorly differentiated adenocarcinomas with desmo-
plastic reaction in the stroma consisting of aSMA-positive
myoﬁbroblasts (Fig. 4E and F). The desmoplastic reaction was
induced in all invaded tumors, suggesting that the AKP or AKT
combination is sufﬁcient to induce ﬁbrotic responses in met-
astatic lesions. In contrast to the primary tumors, the mean
proliferation rate of tumor cells increased gradually from AKP
to AKT, AKTF, AKTP, and AKTPF (Fig. 4G; Supplementary
Fig. S5). Of note, macrophages, CD4þ and CD8þ T cells, and
B cells were inﬁltrated into the metastasized tumors at the
similar levels, regardless of the tumor genotypes, whereas T-cell
inﬁltration was rarely found in the primary tumors of the same
genotype mice (Fig. 4H and I; Supplementary Fig. S5). Accord-
ingly, the interaction with microenvironment in the metasta-
sized tumors contributes to the induction of the host immune
response to tumor cells, although the underlying mechanism
remains to be investigated.
Identiﬁcation of common genes for metastasis induced by the
ApcD716 KrasG12D Tgfbr2/ combination
To examine whether genotype-related malignant phenotypes
are associatedwith distinct expression proﬁles, we next performed
RNA-seqof the tumororganoids for theATP, AKP,AKT, AKTP, and
AKTPF genotypes that showed submucosal invasion in the pri-
mary tumors. Notably, a principal component analysis (PCA)
indicated that expression proﬁles of tumors carrying the KrasG12D
mutation (AK common, i.e., AKP, AKT, AKTP, and AKTPF) were
divergent from that of ATP (Fig. 5A, left), which reﬂected the fact
that Kras activation is required for metastasis. Furthermore, the
expression proﬁles of AKT common (AKT, AKTP, and AKTPF)
organoids were distinct from that of AKP (Fig. 5A, center), which
reﬂected the high metastatic ability of AKT common organoids
compared with AKP. We also found the evolutional expression
changes fromAKT toAKTPF viaAKTP (Fig. 5A, right). These results
suggest that expression changes induced by AKT mutations cause
efﬁcientmetastasis, and additionalmutations in Trp53 and Fbxw7
accelerate malignancy, which is consistent with the results of
phenotype analyses (Fig. 5B).
We next extracted 363 differentially expressed genes (DEG)
in AKT common genotype tumors by selection of overlapping
genes in AKT, AKTP, and AKTPF versus A, respectively (Fig. 5C;
Supplementary Table S2). GO term analysis using AKT com-
mon DEGs indicated signiﬁcantly enriched pathways relating
to angiogenesis, signal transduction, hypoxia, and epithelial
morphogenesis, suggesting the role of these pathways in AKT
combination-induced metastasis (Fig. 5D). Hierarchical clus-
tering analysis indicated that expression pattern of ATP was
divergent from that of AKT common genotypes (Fig. 5E).
Although expression of AKP was distinct from AKT common,
we found 175 overlapping DEGs in AKT common and AKP but
not with ATP (Fig. 5E–G). These results are consistent with
those found by PCA (Fig. 5B). Notably, the expression proﬁle
of AK tumors was similar to that of AKT common. We found
that organoids from AK tumors but not simple ApcD716 tumors
formed submucosal tumors with desmoplastic reactions when
they were injected directly into colonic submucosa (Supple-
mentary Fig. S6). Taken together, these results suggest that the
AK combination signiﬁcantly contributes to the AKT-induced
malignant phenotype.
We thus classiﬁed 363 AKT common DEGs to four clusters of
AKT (CL1,CL2,CL3, andCL5 in Fig. 5F; Supplementary Table S2),
and performed hierarchical clustering analysis. As expected, 73
genes classiﬁed to CL5 showed expression patterns speciﬁc to the
AKT common genotypes, which were not overlapped with AKP
and ATP (Fig. 6A and B). Among 73 AKT-common genes, we
selected 60 genes, 21 upregulated and 39 downregulated, which
were annotated in the TCGA colorectal cancer database, and
extracted expression data of these 60 genes. Importantly, the
mean expressions of upregulated AKT-common genes were sig-
niﬁcantly higher in human colorectal cancer withmetastasis (M1)
than those without metastasis (M0), suggesting that AKT-
common signature is important also for human colorectal cancer
metastasis (Fig. 6C). Moreover, we found that expression levels of
R3HDML and SYT7were signiﬁcantly upregulated inM1 thanM0
colorectal cancer tissues, while those of PSME1 and TMEM150C
were downregulated, which were consistent with those found in
the AKT-common proﬁle (Fig. 6B and C). Of note that SYT7, a
calcium sensor for synapse exocytosis, plays a role in cell migra-
tion (39, 40). Accordingly, it is possible that upregulated genes in
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Figure 4.
Liver metastasis of tumor organoids derived from mice carrying AKP and AKT mutations. A, Incidence of liver and lung metastasis at 4 weeks after
transplantation of the indicated genotype organoids to spleen of C57BL/6 and NSG mice. NT, not tested because of no metastasis in NSG mice. B and
C,Multiplicity of livermetastasis calculated bypercentagesofmetastasized tumor foci in the liver on theH&E sections inNSGmice (B) andC57BL/6mice (meanSD;
C). Each dot indicates individual mice.  , P <0.05.D, Representativemacroscopic photographs (top) and histology sections (H&E, bottom) of livers of C57BL/6mice
transplanted with the indicated genotype organoids. Arrowheads, metastatic foci. Scale bars, 1 cm (top) and 1 mm (bottom). E, Representative photographs
of livermetastasis of the indicatedgenotype organoids inC57BL/6mice (top, H&E lowmagniﬁcation;middle, enlargedhighmagniﬁcation imagesof theboxedarea in
top; bottom, aSMA immunostaining). Scale bars, 200 mm. F, Ratio of aSMA immunostaining–positive area in liver metastasis tumors (mean  SD). G, Ratio of
Ki67-positive tumor cells in liver metastasis tumors (mean  SD). H and I, Ratio of immunostaining-positive area for F4/80 (H) and CD3e (I) in liver metastasis
tumors (mean  SD). Each dot indicates individual mice.  , P < 0.05.
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Figure 5.
Gene expression proﬁles associated with driver mutation-induced malignant progression phenotypes. A, A PCA for sequence results of A, ATP, AKP, AKT,
AKTP, and AKTPF organoids. AKP, AKT, AKTP, and AKTPF are included in the AK common group (left; blue), and AKT, AKTP, and AKTPF are included in the
AKT common group (center; blue). B, Schematic model of the evolutionary changes in the gene expression pattern in association with malignant progression
phenotypes based on the results of the PCA in A. C, Venn diagram for overlapping DEGs in AKT, AKTP, and AKTPF versus A. The number of extracted genes and
cluster names are indicated. D, Functional annotations by GO term analysis using 363 AKT common DEGs are shown (log of P values). E, Hierarchical clustering
analysis of theAKT commonDEGs is shown as fold changes of RPKM comparedwith themean. F,Venn diagram for overlappingDEGs in AKT, ATP, andAKP versus A.
The number of extracted genes and cluster names (CL1–7) are indicated. G, The number of AKT common DEGs overlapped in each cluster of AKT DEGs in F.
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AKT-common proﬁle will be effective therapeutic targets for
colorectal cancer metastasis.
Discussion
To understand how the speciﬁc combinations of driver muta-
tions promote each step for colorectal cancer malignant progres-
sion,weperformed comprehensive phenotype characterization of
the primary intestinal tumors and liver metastasis in mouse
models that carried various driver mutations in combination
(Fig. 7). Among the driver genes examined in this study, the
activation mutation of Kras is essential for EMT-like morphology
and metastasis. This is consistent with the previous reports that
liver and lung metastasis of human colorectal cancer are more
likely to develop in patients whose tumors have KRASmutations
(41, 42). In addition, a recent genetic study indicated that the
continuous expression of activated Kras is required for the main-
tenance of invasive and metastatic disease (23). In this study, we
found that the KrasG12Dmutation induced EMT-like morphology
of ApcD716 mouse tumors when combined with mutations in
either of Fbxw7/, Tgfbr2/, or Trp53R270H. Furthermore, Kras
activation promoted intravasation and efﬁcient liver metastasis
when combined with ApcD716 and Tgfbr2/ mutations (AKT
common; Fig. 7). In contrast, the combination of ApcD716 and
Figure 6.
Extracted DEGs speciﬁc to AKT-common genotype tumors. A, Hierarchical clustering heatmaps of the AKT-common DEGs that are classiﬁed to
the respective clusters of AKT (CL1, CL2, CL3, and CL5) are shown as fold changes of RPKM compared with the mean. B, The clustering heatmap of the
AKT-common DEGs classiﬁed to CL5 cluster in A is shown with gene symbol. Gene symbols indicated by red are upregulated or downregulated also in
human colorectal cancer with metastasis. C, Expression analysis of the mean AKT-common upregulated genes (AKT-up) and that of AKT-common
downregulated genes (AKT-down), and the indicated genes in human colorectal cancer tissues with metastasis (M1) or without metastasis (M0). P values
are indicated in red.
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KrasG12Dmutationswas not sufﬁcient for invasion, indicating that
malignant progression by Kras mutation requires other driver
mutations in combination.
We previously showed that either TGFb signaling suppres-
sion or mutant p53R270H expression induces submucosal inva-
sion of ApcD716 mouse tumors (20–22). Consistently, com-
pound mice that carried AT or AP mutations in their genotypes
consistently developed invasive adenocarcinoma. Unexpected-
ly, however, simultaneous mutations of Tgfbr2/ and
Trp53R270H did not induce further intravasation or metastasis,
and the expression proﬁle of ATP organoids was divergent from
that of metastatic AKP and AKT organoids. These results con-
ﬁrm the requirement of a Kras mutation in addition to either
TGFb suppression (AKT) or p53 mutation (AKP) for metastasis
of colorectal cancer (Fig. 7).
On comparing phenotypes between AKP and AKT tumors, AKT
showed markedly more advanced malignancy, such as lymph
vessel invasion and signiﬁcantly higher incidence andmultiplicity
of metastasis in the liver. Interestingly, the expression proﬁles of
AKTP and AKTPF more closely resemble that of AKT than AKP;
therefore, we would like to propose that Wnt activation, Kras
activation, and TGFb suppression (i.e., AKT) are core-combina-
tion pathways for efﬁcient metastasis, and the selected AKT
common DEGs play a role in this process (Fig. 6B). Importantly,
themean expression level of AKT-commonupregulated geneswas
signiﬁcantly increased in human colorectal cancer withmetastasis
(M1), suggesting that AKT-common signature is important also
for metastasis of human colorectal cancer. Moreover, we found
that Syt7 is upregulated both in AKT-common genes and human
colorectal cancer with metastasis. Synaptotagmin (Syt) is a well-
established calcium sensor for calcium-induced exocytosis of
synaptic vesicles (39). Notably, it has been shown that Syt7-
mediated vesicle fusion regulates the chemotaxis of leukocytes
(40). Accordingly, it is possible that Syt7 plays a tumor-promoting
role by accelerating the migration of colorectal cancer cells.
Accordingly, activated pathways by AKT-commonmutationsmay
play a role in malignant progression of human colorectal cancer.
In contrast, it has been shown that the TGFb pathway is
activated in the invasive tumor cells of Apc Trp53Null KrasG12D
mice (23) and that TGFb signaling in the stroma facilitates
tumorigenesis through the promotion of ﬁbrosis and immune
evasion (43). Accordingly, it is possible that TGFb signaling in the
stroma plays a role in the malignant progression of AKT tumor
cells that have lost their TGFb signaling.
In this study, we also found that a desmoplastic reaction is
induced in submucosal tumors and liver metastasis, while
such ﬁbrotic reactions were rarely found in noninvading mucosal
tumors of the same mice. Notably, the histologic features
of tumors were distinctively more malignant in the invasive
and metastatic lesions, suggesting that desmoplastic stroma
Figure 7.
A schematic drawing of the genotype–phenotype relationship in multistep tumorigenesis. Metastasis phenotypes (right) are based on the results of
organoid transplantation to the spleen. AF and AKF were not examined for the metastasis assay (gray). In this study, survival of circulating tumor cells (CTC)
was not evaluated for the respective genotypes.
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contributes to the induction ofmalignant phenotypes. It has been
reported that ﬁbrosis with the deposition of type I collagen
promotes metastasis by inducing the proliferation of dormant
cells via integrin signaling (37, 44, 45), and collagen crosslinking
in the stroma results in the promotion of invasion andmetastasis
(46). Therefore, it is possible that EMT-like morphology and
metastasis of AKT tumors are induced by cooperation of driver
mutations and ﬁbrotic microenvironment.
The disruption of Fbxw7 increased the number of intestinal
tumors in ApcMin mice (16, 17); however, its role in malignant
progression remains unclear. In this study, we showed that the
combination of the Fbxw7/ and KrasG12D mutations (AKF)
induced EMT-like morphology in mucosal tumors without the
support of ﬁbrotic microenvironment (Fig. 7). It has been
shown that Fbxw7 plays a role in stem cell regulation, and its
deletion accelerates the self-renewal activity of stem cells (47).
Furthermore, there is a direct link between EMT and the gain of
epithelial stem cell properties (48). It is therefore possible that
Fbxw7 disruption leads to EMT-like morphology through the
acquisition of stem cell properties, which may contribute to the
increased multiplicity of metastasis of AKTPF tumors compared
with AKTP.
In this study, we did not ﬁnd spontaneousmetastasis to distant
organs in any genotype mice, even if tumor cells can invade into
vessels andmetastasize to liver from spleen (Fig. 7). It is therefore
possible that additional genetic or epigenetic alteration(s) are
required to overcome physical stresses in the blood stream and
escape from immune attack, which are required to be survived as
circulating tumor cells (Fig. 7; ref. 37).
Microsatellite instability (MSI)-high colorectal cancer is asso-
ciated with an increased level of immune cell inﬁltration (49),
therefore, MSI-high colorectal cancer responds to immune check-
point blockade (50). However, the association with tumor-inﬁl-
trating lymphocytes was also evident in microsatellite-stable
colorectal cancer tumors (7), indicating that non-MSI colorectal
cancer also can induce an immune reaction. In this study,
we found that both CD4þ and CD8þ T cells inﬁltrated into
metastasized tumors of C57BL/6 mice at the similar level among
all genotypes, although T-cell inﬁltration was rarely detected even
in the invasive area of the primary tumors. These results suggest a
mechanism of the microenvironment in the metastasized tumors
to induce immune responses against non-MSI colorectal cancer
cells, although further studies will be needed. This mechanism is
particularly important for understanding tumor immunity, which
will help develop therapeutic strategies for preventing colorectal
cancer metastasis in the future.
In conclusion, we constructed mouse models with multiple
combinations of driver mutations and performed the compre-
hensive characterization of the primary and metastatic tumors.
Suppression of the TGFb pathway or expression of mutant p53
induces submucosal invasion, and additional Kras mutation
activation is required for further malignant progression including
EMT-like morphology, intravasation, and metastasis. In contrast,
the combination of Fbxw7 inhibition and Kras activation induces
EMT-like morphology, possibly through increased stemness.
Finally, Wnt activation, Kras activation, and TGFb suppression
represent important combination for efﬁcientmetastasis, which is
corroborated by the RNA-seq analysis. Accordingly, pathways
activated by the AKT-common DEGs may be preventive or ther-
apeutic targets against colorectal cancer metastasis.
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